With Record Attendance, AACR 2023 Spotlights Diagnostics

Protein and molecular-based research and diagnostics, including multiplexed bead-based assays, were front and center at the 2023 cancer research conference

[thumbnail]

Every year, thousands of the world’s leading cancer researchers convene to share the latest scientific advances and clinical research discoveries at the annual meeting of the American Association for Cancer Research. The Luminex team was excited to attend another insightful AACR annual meeting at the Orange County Convention Center in Orlando, Fla., where more attendees than ever gathered for the event.

The era of genomics and rapid progress in cancer research

After decades of slow but steady progress in understanding the underlying mechanisms of cancer, the era of genomics has transformed the pace of cancer research. We love attending the annual AACR meeting because it provides a great snapshot of the most exciting recent developments in the genomic advancements in cancer research, as well as a reminder of just how quickly these advances are happening. From large-scale genomics studies to deep dives into the interplay of a tumor and surrounding environment, the results reported at AACR meetings are likely to drive improvements in how cancer is treated in the future. This year, a track about multiomics in diagnosis and care management was especially popular, and sessions of particular interest to us include those on the biology of early cancers, precision prevention, and early cancer detection.

Advancements in molecular diagnostics: spotlight on xMAP® multiplexing technology

In addition, we were eager to see several posters highlighting the use of xMAP® Technology applications in cancer research. One from Hideki Furuya, PhD, a scientist at Cedars-Sinai Medical Center in Los Angeles, illustrated how Furuya and his team used Bio-Techne assays based on xMAP Technology to detect, monitor, and predict urothelial carcinomas. It was an impressive demonstration of how multiplexing technology can help scientists achieve more than they could with conventional single-plex tests.

Another poster from Cuipeng Qiu and colleagues at the University of Texas at El Paso showcased how scientists developed a panel of anti-tumor associated autoantibodies for detecting prostate cancer. Furthermore, two additional posters were presented by scientists at Millipore Sigma: one featuring immune checkpoint biomarkers in mouse tumor models, and another about a 48-plex cytokine assay for colorectal cancer.

Introducing the upgraded xMAP INTELLIFLEX® System

Another AACR 2023 conference highlight occurred at our booth in the exhibit hall, where it was an honor to share the newest capabilities of our xMAP INTELLIFLEX System. With a recent software update, the system is now more flexible, secure, and easy to use, as it incorporates optional modules to enable integration in an automated workflow, electronic records compliance for 21 CFR Part 11 and EU Annex 11, as well as improvements to the user experience.

These updates make the xMAP INTELLIFLEX System a great fit for research that must comply with regulatory oversight and cybersecurity requirements, such as many cancer studies conducted by pharmaceutical and biotech companies. We’ll be rolling out the new software gradually throughout this year.

We hope you had as much fun at AACR as we did. We’re already looking forward to next year’s conference in San Diego!

Keep up with the latest from Luminex year-round and find out which events we’ll be attending by subscribing to the xMAP Resource Round-Up email newsletter—your source for the latest research, resources, and updates for all things xMAP.

Sign up now >>

Related Content:

Partner Spotlight: ImmunoProfile®

Understanding one’s disease protection begins with confidently knowing one’s antibody status

Co-Authored by Jessica Schneider

[thumbnail]

Inspired by the inventive ways our Luminex Partners benefit healthcare, we spotlight one of our newest Partners, ImmunoProfile®. Founded by two veterans in the medical devices industry, ImmunoProfile® offers an IgG serology test panel to easily learn your antibody protection level to each of 11 different infectious diseases. The pathogens they test antibodies for include Hepatitis A, Hepatitis B, H. Influenza B, Measles, Mumps, Rubella, Tetanus, Diphtheria, Pertussis, Varicella Zoster/Chicken Pox, and Polio. One of the advantages of this company’s testing service is the convenience it offers customers through online ordering and an at-home specimen collection kit that utilizes a single finger-prick blood sample. Through the testing of dried blood spots, ImmunoProfile can then evaluate antibody levels of each of the 11 different infectious diseases, all of which are vaccine preventable according to the CDC.

Reliable Results with ImmunoProfile’s Technology

ImmunoProfile’s goal is to “empower people everywhere to protect themselves from infectious diseases,” achieving this by placing the power into the hands of private individuals through an easily accessible affordable system with the convenience of at-home testing. Using the FDA-cleared Luminex technology, the antibody test results are evaluated against World Health Organization (WHO) established standards. Rather than having to travel to a medical facility, customers can obtain their highly accurate and affordable results through a secure and private online portal after they’ve provided their at-home finger-prick blood specimen and mailed it in the pre-addressed UPS envelope to the company’s CLIA/CAP-certified lab. The test is available in all 50 states and Washington, D.C. and HSA/FSA payments are accepted.

The Power of xMAP® Technology in Multiplexing Assays

As part of a growing number of Luminex Partners offering testing services to the public, ImmunoProfile seeks to advance healthcare by applying its business model to a science that is both accessible and affordable. And what is the foundation behind this science? xMAP® Technology. One of the many advantages of Luminex’s multiplexing platform is that it allows users to simultaneously detect up to 500 targets in a single well, providing customized flexibility for both proteomic and genomic assays.

Advancing Healthcare with Innovative Testing Solutions

Partners like ImmunoProfile demonstrate how xMAP Technology is a reliable and well-established multiplexing technology that has performed successfully throughout many markets, including RUO, clinical diagnostics, non-diagnostic at-home sample collection, and others. As with ImmunoProfile, understanding one’s disease protection level begins with confidently knowing one’s antibody status. Be sure to visit their website to learn more about the services performed at ImmunoProfile.

Furthermore, if you are interested in learning more about xMAP Technology for your own testing needs please visit our website and request to speak with our sales team to learn more about our multiplexing platform and benefits of becoming a partner.

Become a Luminex Partner Today!

Related Content:

World Vaccine Congress: The Growing Need for High-Quality Immune Profiling

Recent innovation in vaccine development spotlights the demand for robust technology to measure cytokines, immunoglobulins, and more

[thumbnail]

The Luminex team was pleased to attend this year’s World Vaccine Congress, which took place in April in Washington, DC. With so much innovation in vaccine development and commercialization occurring globally, it was exciting to learn about the latest advancements from some of the field’s leaders.

The Growing Need for Reliable Immune Profiling Technologies in Vaccine Development

The event’s highlights spanned the vaccine development spectrum, from basic research to manufacturing. We heard from government and regulatory experts, pharmaceutical executives, and scientists from leading vaccine research institutions. Along with thousands of attendees, we learned about new findings and progress related to the mRNA vaccine durability research, rational vaccine design, supply and logistics planning, and immune profiling.

world vaccine week presenter

xMAP® Technology: Providing Comprehensive Immune Profiling Insights for Vaccine Development

We were also honored to have our own Dominic Andrada provide a presentation during the meeting’s Immune Profiling session. In his talk, titled “Updated Strategies for Immune Profiling in Vaccine Development with xMAP® Technology,” he explained that immune profiling is a popular application for xMAP Technology because its unique multiplexing capacity allows for truly comprehensive and quantitative views of the many components involved in immune response. This is particularly relevant to the vaccine development community, where advances in mRNA vaccines, cancer vaccines, recombinant antigens, and new adjuvants, among other factors, have been driving demand for immune profiling data.

With so many new avenues for vaccine development, it’s important to have a robust, reliable technology for these immune profiling experiments. As the global community moves beyond its three-year focus on COVID-19 vaccines, there will be a strong need to understand cellular immune response in vaccine candidates.

Applications of xMAP Technology in Vaccine Development

For many xMAP users, cytokine measurement in vaccine response is a key area of interest, and this is an especially good fit for our xMAP INTELLIFLEX® System, which has an optional dual-reporter channel to measure closely related analytes. Relevant real-world examples include an analysis of IgG and IgM antibody responses to SARS-CoV-2 antigens and the use of xMAP Technology to develop a cost-effective COVID-19 vaccine, known as Corbevax at Baylor’s Center for Vaccine Development.

Other relevant applications of our multiplexing technology include the identification of secreted proteins, mechanism of action studies, pathogen detection, genotyping, the measurement of protein-protein interactions, and more.

Request a copy of the immune profiling presentation or learn more about the use of xMAP Technology in vaccine development.

Request the Immune Profiling Presentation

xMAP Technology In Vaccine Development

Related Content:

xMAP® Connect: Detecting Early Risk of Stroke with a Multiplex Immunoassay

Scientists are using xMAP® Technology to develop a new assay for vascular brain injury

Dr. Jason Hinman

Attendees of our latest xMAP® Connect event learned about the impact of multiplex testing for patients with vascular brain injury from Jason Hinman: Associate Professor at the University of California, Los Angeles and President of Sage Cerebrovascular Diagnostics.

Dr. Hinman and his team developed a new assay for vascular brain injury using xMAP® Technology, making it possible to detect early risk of stroke with a multiplex immunoassay.

Detecting Early Risk of Stroke with a Multiplex Immunoassay

Hinman and his team aimed to develop a blood-based test able to detect key indicators of vascular brain injuries that increase the risk of stroke and dementia. Stroke, for instance, is a leading cause of disability and death around the world, Hinman noted. A more effective test to detect “silent” brain injuries would make it possible to improve treatment for those most in need.

A Multiplex Immunoassay for Vascular brain injury

At the beginning of this effort, Hinman was already acquainted with xMAP Technology, which he had previously used to measure cytokine activity associated with inflammatory signaling in the brain. His familiarity with xMAP Technology inspired him to continue utilizing the bead-based platform for his novel cerebrovascular test, which would aim to diagnose the presence of severe, silent brain injuries. The new assay, which was evaluated on patients at the Ronald Reagan UCLA Medical Center Emergency Room included six biomarkers and generated a composite score of 94% specificity using blood or serum samples.

“The Luminex xMAP Technology is really optimal for the challenge we are facing because it allows us to build a multiplex assay now that we can continue to augment in the future and it allows us to quickly scale,” Hinman explained.

Minimizing Cross-Reactivity in the Cerebrovascular Test

In his presentation, Hinman also spoke about the challenges of assay development and commercialization. His team worked with Luminex partner, Bio-Techne, to obtain robust antibodies for their desired targets. They also spent quite a bit of time minimizing cross-reactivity, ensuring strong performance across Luminex devices, and optimizing additional assay details.

Now, the assay will be tested in NIH-funded studies of up to 14,000 patients. Hinman’s team plans to launch it initially as a laboratory-developed test.

Watch the Presentation Now On-Demand

Watch the on-demand presentation now by visiting our xMAP Connect Virtual Conference Hub on Labroots. While you’re there, be sure to check out more presentations from the xMAP Connect event in La Jolla to learn more about the latest advancements in multiplexing technology.

We hope to see you at the next xMAP® Connect event in Atlanta, GA this November to learn about the latest advancements in multiplexing technology.

Watch Now >>

Read highlights from several more presentations from xMAP Connect in these related blogs:

Video Demonstration: Monitoring Immune Response with a Dual-Reporter System

New JoVE video shows how to monitor immune response associated with COVID-19

[thumbnail]

Early in the COVID-19 pandemic, researchers at Rush University Medical Center in Chicago developed and validated a multiplex serological assay to test for antibodies targeting four different antigens of the SARS-CoV-2 virus. The assay was based on xMAP® Technology and can track exposure to the virus based on antibodies targeting its spike, nucleocapsid, membrane, or envelope proteins.

Now, the same team has created a helpful video tutorial for anyone interested in monitoring the immune response to a COVID-19 vaccine or SARS-CoV-2 infection. The team’s method demonstrates how to measure dynamic antibody titer changes in IgA, IgM, or IgG. A multiplex reader with dual-reporter capacity, such as the xMAP INTELLIFLEX, allows users to check two of the three immunoglobulins at one time.

Published by the online video journal JoVE, the step-by-step protocol comes from lead authors Cristina Fhied, Imad Tarhoni, and senior author Jeffrey Borgia. “This approach allows us to evaluate multiple epitopes on the same analyte,” Borgia explains in the video.

In the demonstration, Tarhoni performs and describes each step in the workflow. He shows how different time frames can be tested — he used increments of 30, 60, and 120 minutes — to compare results and determine which is best suited to achieve the desired results.

“This method has important implications for monitoring response to vaccines in immunocompromised individuals,” Borgia concludes. “It will permit us to determine if these patients are truly getting protected by these vaccinations.”

To learn more about the dual-reporter capabilities of our new xMAP INTELLIFLEX® System, check out this overview.

Discover the Possibilities >>

For Research Use Only. Not for use in diagnostic procedures.

xMAP Technology at PepTalk 2023

PepTalk 2023: An Overview

Last month, scientists working in drug discovery and biologics development were treated to an informative and insightful PepTalk 2023 conference in San Diego, CA from January 16-20. More than 850 participants from top global pharma, biotech, academic, and governmental institutions convened to learn about the latest scientific advancements in cutting-edge biologic therapies.

[thumbnail]

Specific areas of focus included Antibody Discovery & Engineering, Bispecific Antibody Development, Characterization of Biotherapeutics & Vaccines, Cell & Gene Therapy, Biotherapeutic Expression & Production, and Process Technology & Innovation.

The Pursuit of Better Outcomes with New Biologic Therapies

While monoclonal antibody (mAb) therapeutics comprise the majority of new biologics, new modalities are being developed to better treat patients and improve disease outcomes. These new therapeutic modalities may specifically target solid tumors, decrease off-target effects resulting in lower toxicity, and recruit the body’s immune system to express proteins that fight chronic disease.

Many of these new biologic therapies are designed and built as individual components before they are assembled to form active drug products, unlike small molecular weight (SMW) drugs or a specific mAb. This provides added therapeutic utility; for biologics such as antibody drug conjugates (ADCs), bispecific antibodies, mRNA vaccines, and cell and gene therapies, it also increases the complexity of manufacturing. The added complexity often requires multiple bioanalytical techniques for measuring toxicity and intended therapeutic effects.

While Luminex assays are well known in drug discovery, several sessions discussed xMAP® Technology also being used in process development and manufacturing stages for mRNA vaccines. xMAP’s ability to measure hundreds of proteins or genomic targets in a sample provides unmatched comprehensive analysis on a single platform. Custom built Luminex assays—particularly those that measure specific impurities and residual host-cell proteins—also provide greater utility for reliably assessing the safety of these new biologics.

Updated Regulatory Guidelines

Another hot topic at the conference was the response from regulatory agencies, such as the FDA and EMA, to these novel biologics therapies. These regulatory agencies are updating guidance documents in both the USA and Europe, and are working with industry sponsors to clarify parameters for the proper manufacture, quality characterization, and safety assessment of these new therapies.

Learn more about Luminex’s revolutionary xMAP Technology for multiplex immunoassays, and explore today how Luminex technology can advance your lab work to the next level.

Learn More >>

For Research Use Only. Not for use in diagnostic procedures.

Clinical and Laboratory Standards Institute Honors Dr. Sherry Dunbar

Award recognizes substantial time and effort in supporting clinical lab standards and guidelines

As a dedicated participant in the clinical lab community, we are honored to have a member of our team recognized by the prestigious Clinical and Laboratory Standards Institute (CLSI). Congratulations to Dr. Sherry Dunbar, Senior Director of Scientific Affairs here at Luminex, for winning CLSI’s Excellence in Standards Development Award!

[thumbnail]

This annual award is bestowed upon a volunteer who goes above and beyond in the development, implementation, or promotion of laboratory standards and guidelines. The award is open to any CLSI member, and winners are chosen by the institute’s Awards Committee and executive leadership.

— CLSI
“These awards celebrate the achievements of CLSI volunteers and organizational members who are committed to CLSI’s mission and have helped improve the quality of medical care worldwide.”